The primary objective is to determine the safety and efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary indeterminate lesions (IL) or small choroidal melanoma (CM).
Choroidal Melanoma, Indeterminate Lesions, Uveal Melanoma, Ocular Melanoma
The primary objective is to determine the safety and efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary indeterminate lesions (IL) or small choroidal melanoma (CM).
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects with Primary Indeterminate Lesions or Small Choroidal Melanoma
-
Retina Consultants of Alabama, Birmingham, Alabama, United States, 35233
UCSD Shiley Eye Institute, Jacobs Retina Center, La Jolla, California, United States, 92093
Doris Stein Eye Research Center, Los Angeles, California, United States, 90095
Stanford University School of Medicine, Palo Alto, California, United States, 94303
Retinal Consultants Medical Group, Inc., Sacramento, California, United States, 95825
UCSF Ocular Oncology Clinic, San Francisco, California, United States, 94143
Colorado Retina Associates, Lakewood, Colorado, United States, 80228
Bascom Palmer Eye Institute, Miami, Florida, United States, 33136
Retina Associates of Florida, PA, Tampa, Florida, United States, 33609
Emory Eye Center, Atlanta, Georgia, United States, 30322
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
Aura Biosciences,
Medical Monitor, STUDY_DIRECTOR, Aura Biosciences
2027-03-01